Pacific Biosciences Of California (PACB) Cost of Revenue (2011 - 2026)

Pacific Biosciences Of California has reported Cost of Revenue for 16 years, with the latest figure at $26.4 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 5.13% year-over-year to $26.4 million in Q2 2026; TTM through Jun 2026 was $101.3 million, a 17.44% decrease from a year earlier, with the FY2025 full-year figure at $114.2 million, down 2.15% from the prior year.
• Cost of Revenue was $26.4 million for Q2 2026 at Pacific Biosciences Of California, up from $24.3 million in the prior quarter.
• The five-year high for Cost of Revenue was $48.8 million in Q4 2023, with the low at $18.8 million in Q3 2022.
• Average Cost of Revenue over 5 years is $28.3 million, with a median of $27.8 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue soared 119.63% in 2023, then plunged 40.22% in 2024.
• Over 5 years, Cost of Revenue stood at $22.2 million in 2022, then surged by 119.63% to $48.8 million in 2023, then slumped by 40.22% to $29.2 million in 2024, then decreased by 3.73% to $28.1 million in 2025, then decreased by 6.09% to $26.4 million in 2026.
• The last three Cost of Revenue figures came in at $26.4 million (Q2 2026), $24.3 million (Q1 2026), and $28.1 million (Q4 2025), per Business Quant data.